Survodutide is a glucagon/GLP-1 dual agonist with a finished phase 3 obesity trial, and it has more published dosing detail than most unapproved molecules: Boehringer Ingelheim posted the phase 2 escalation week by week, and the first phase 3 result appeared in the NEJM in 2026. It has no label. This page reports what the trials gave, how the doses were reached, what the trials found at each dose, and the syringe arithmetic for the research-vial sizes.
The compound itself — mechanism, the liver programme and the evidence — is covered in Medibact's Survodutide guide. The survodutide calculator works any vial and volume.
Doses in the registered trials
| Trial | Population | Weekly doses | Source |
|---|---|---|---|
| SYNCHRONIZE-1, phase 3 (NCT06066515) | 725 adults with obesity, no diabetes | escalated to 3.6 or 6.0 mg | NEJM 2026 |
| SYNCHRONIZE-2, phase 3 (NCT06066528) | 755 adults with obesity and type 2 diabetes | escalated to 3.6 or 6.0 mg | design paper; no results posted |
| Phase 2, obesity (NCT04667377) | 387 adults, BMI ≥27 | 0.6, 2.4, 3.6 or 4.8 mg after 20 weeks of escalation | Lancet Diabetes Endocrinol 2024; results posted |
| Phase 2, liver disease (NCT04771273) | 295 adults with biopsy-proven MASH | planned maintenance 2.4, 4.8 or 6.0 mg | results posted |
| Phase 2, type 2 diabetes (NCT04153929) | 413 adults on metformin | 0.3, 0.9, 1.8 or 2.7 mg weekly; 1.2 or 1.8 mg twice weekly; open-label semaglutide comparator | results posted |
| Phase 1, cirrhosis (NCT05296733) | people with and without cirrhosis | single 0.3 mg; then 0.3 escalated to 6.0 mg over 24 weeks | J Hepatol 2024 |
ClinicalTrials.gov listed 33 survodutide studies on 2026-09-26: 9 phase 3, 4 phase 2, 20 phase 1. The trials read for this page all give it under the skin, and all but two phase 2 arms give it once a week.
How the doses were reached
The phase 2 obesity trial's posted participant-flow records spell out each arm's escalation. Doses rose every two weeks, fixed to week 10 and flexible from week 11 to week 20:
| Weeks | 2.4 mg arm | 3.6 mg arm | 4.8 mg arm |
|---|---|---|---|
| 1–2 | 0.3 mg | 0.3 mg | 0.3 mg |
| 3–4 | 0.6 mg | 0.6 mg | 0.6 mg |
| 5–6 | 0.9 mg | 0.9 mg | 0.9 mg |
| 7–8 | 1.2 mg | 1.2 mg | 1.2 mg |
| 9–10 | 1.2 mg | 1.2 mg | 1.8 mg |
| 11–12 | 1.8 mg | 1.8 mg | 2.4 mg |
| 13–14 | 1.8 mg | 2.4 mg | 3.3 mg |
| 15–16 | 2.4 mg | 3.0 mg | 4.2 mg |
| 17–20 | 2.4 mg | 3.6 mg | 4.8 mg |
Each weekly dose was given as two 0.5 mL injections on the same day, so every arm injected the same volume regardless of dose — a blinding device, not a concentration anyone reproduces from a research vial. Maintenance ran from week 21 to week 46.
Phase 3 changed this. Boehringer's design paper for SYNCHRONIZE-1 and -2 says the phase 1 and 2 escalations, every two weeks, were more rapid than for similar drugs and that gastrointestinal events clustered during escalation; the phase 3 scheme was lengthened, allows one or two re-escalation attempts and permits staying at a dose for 2 to 4 weeks. The paper does not print the week-by-week table.
What the trials found at each dose
| Trial and dose | Weight change | Placebo | Duration |
|---|---|---|---|
| Phase 2, 0.6 mg | −6.2% | −2.8% | 46 weeks |
| Phase 2, 2.4 mg | −12.5% | −2.8% | 46 weeks |
| Phase 2, 3.6 mg | −13.2% | −2.8% | 46 weeks |
| Phase 2, 4.8 mg | −14.9% | −2.8% | 46 weeks |
| SYNCHRONIZE-1, 3.6 mg | −12.2% | −5.4% | 76 weeks |
| SYNCHRONIZE-1, 6.0 mg | −13.0% | −5.4% | 76 weeks |
Phase 2 figures are by planned dose; the design paper's "up to 18.7%" is the same trial analysed by dose actually received. The phase 3 figures count everyone randomised, including those who stopped, which usually gives smaller numbers. The gap between 3.6 mg and 6.0 mg in phase 3 was 0.8 percentage points, while gastrointestinal events rose from 80.9% to 89.7%. In phase 2, 281 of 309 people on survodutide (91%) reported an adverse event and 122 of 309 did not complete the 46 weeks.
Tolerability shaped the doses more than for most compounds in this catalogue. In a Japanese phase 1 study (PMID 36974349), 10 of 27 men on survodutide withdrew from escalation for adverse events — 6 of the 9 aiming for 4.8 mg weekly.
Units at the phase 2 and phase 3 doses
Units on a U-100 syringe = mg ÷ mg/mL × 100. Research vials in this site's data come in 5, 10 and 15 mg:
| Dose | 2.5 mg/mL (5 mg + 2 mL) | 5 mg/mL (5 mg + 1 mL, 10 mg + 2 mL) | 7.5 mg/mL (15 mg + 2 mL) | 10 mg/mL (10 mg + 1 mL) |
|---|---|---|---|---|
| 0.3 mg | 12 | 6 | 4 | 3 |
| 0.6 mg | 24 | 12 | 8 | 6 |
| 1.2 mg | 48 | 24 | 16 | 12 |
| 2.4 mg | 96 | 48 | 32 | 24 |
| 3.6 mg | 144 | 72 | 48 | 36 |
| 4.8 mg | 192 | 96 | 64 | 48 |
| 6.0 mg | 240 | 120 | 80 | 60 |
Figures above 100 exceed one 1 mL syringe. The trials' low steps — 0.3 mg at 10 mg/mL is 3 units — are where a high concentration reads least precisely; the insulin syringe units page covers the smaller barrels. The mg to units page sets out the formula.
Against the other glucagon-GLP-1 molecules
Survodutide is dosed in the same milligram range as tirzepatide and retatrutide but reached its phase 3 doses through smaller steps from 0.3 mg. The GLP-1 dosage chart sets approved products and trial molecules side by side; retatrutide's dosage page reports the other agonist with a glucagon component.
What is not established
No regulator has reviewed a survodutide dose. The phase 3 escalation table is unpublished; SYNCHRONIZE-2 and the cardiovascular trial had no posted results on 2026-09-26; no half-life figure was found in the published abstracts. Research-market survodutide has no data of its own, and whether it matches Boehringer's molecule is not known. The unit figures are arithmetic. Nothing on this page is a dose or a schedule.
Sources and dates
Opened 2026-09-26: ClinicalTrials.gov v2 search for survodutide and BI 456906 (33 studies) and the records for NCT06066515, NCT06066528, NCT04667377 (posted participant-flow group descriptions), NCT04771273, NCT04153929 and NCT05296733; PubMed abstracts for le Roux et al., NEJM 2026 (PMID 42253238), le Roux et al., Lancet Diabetes Endocrinol 2024 (PMID 38330987, with its conflict statement), Lawitz et al., J Hepatol 2024 (PMID 38857788), Yazawa et al., Diabetes Obes Metab 2023 (PMID 36974349), Jungnik et al., Diabetes Obes Metab 2023 (PMID 36527386) and Klein et al., Diabetes Res Clin Pract 2024 (PMID 37330144); full text of Wharton et al., Obesity 2025 (PMC11664303); DailyMed search for survodutide. The trials were funded by Boehringer Ingelheim. Unit figures are arithmetic by this site. Corrections go to the contact page.